The relative levels of cyclin D1a and D1b alternative transcripts in mantle cell lymphoma may depend more on sample origin than on CCND1 polymorphism

Haematologica

Volumn 90, Issue 6, 2005, Pages 854-856

  Carrère, Nathalie ^b   Belaud Rotureau, Marc Antoine ^b   Dubus, Pierre ^b   Parrens, Marie ^b   De Mascarel, Antoine ^b   Merlio, Jean Philippe ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b NONE

Author keywords

CCND1 gene polymorphism; Cyclin D1; Mantle cell lymphoma; Real time RT PCR quantification

Indexed keywords

CD19 ANTIGEN; COMPLEMENTARY DNA; CYCLIN D1; CYCLIN D1A; CYCLIN D1B; ISOPROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BONE MARROW; CANCER GROWTH; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION 11; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; EXON; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRON; LYMPH NODE; MANTLE CELL LYMPHOMA; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPLEEN; TISSUE SPECIFICITY;

EID: 21244489557     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Motokura T, Arnold A. PRAD1/cyclin D1 proto-oncogene: genomic organization, 5′ DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. Genes Chromosomes Cancer 1993;7:89-95.
2. Rosenwald A, Wright G, Wiestner A, Chan WC, Connors JM, Campo E, et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mande cell lymphoma. Cancer Cell 2003;3:185-97.
3. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995;11:1005-11.
4. Hosokawa Y, Tu T, Tahara H, Smith AP, Arnold A. Absence of cyclin D1/PRAD1 point mutations in human breast cancers and parathyroid adenomas and identification of a new cyclin D1 gene polymorphism. Cancer Lett 1995;93:165-70.
5. Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H, et al. Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 1998;16: 1701-12.
6. Holley SL, Parkes G, Matthias C, Bockmuhl U, Jahnke V, Leder K, et al. Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck. Am J Pathol 2001;159:1917-24.
7. Porter TR, Richards FM, Houlston RS, Evans DG, Jankowski JA, Macdonald F, et al. Contribution of cyclin dl (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer. Oncogene 2002;21:1928-33.
8. Howe D, Lynas C. The cyclin D1 alternative transcripts [a] and [b] are expressed in normal and malignant lymphocytes and their relative levels are influenced by the polymorphism at codon 241. Haematologica 2001;86:563-9.
9. Howe JG, Crouch J, Cooper D, Smith BR. Real-time quantitative reverse transcription-PCR for cyclin Dl mRNA in blood, marrow, and tissue specimens for diagnosis of mande cell lymphoma. Clin Chem 2004;50:80-7.
10. Yang W, Agrawal N, Patel J, Edinger A, Osei E, Thut D, et al. Diminished expression of CD19 in B-cell lymphomas. Cytometry B Clin Cytom 2005;63B:28-35.
11. Uchimaru K, Taniguchi T, Yoshikawa M, Asano S, Arnold A, Fujita T, et al. Detection of cyclin D1 (bcl-1, PRAD1) overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)(q13;q32)- bearing B-cell malignancies and/or mantle cell lymphoma. Blood 1997;89:965-74.